Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Gregory B Lesinski"'
Autor:
Gregory B. Lesinski, Ibrahim Halil Sahin, Sujata R. Kane, Clifford J. Gunthel, Jessica Guadagno, Edith Brutcher, Christina Wu, Bassel F. El-Rayes, Katherine Emilie Rhoades Smith
Publikováno v:
JCO Oncology Practice. 16:319-325
Recent studies have identified durable responses with the use of immune checkpoint inhibitors in patients with mismatch repair–deficient (MMR-D)/microsatellite instability–high (MSI-H) metastatic colorectal cancer (CRC). The dramatic improvement
Autor:
Gregory B. Lesinski, Kabir Mody, Denise Lau, Anthony B. El-Khoueiry, Nilofer S. Azad, Rachna T. Shroff, Mark Yarchoan, Prerna Jain, Robin Kate Kelley, Sherif El-Refai
Publikováno v:
Journal of Clinical Oncology. 39:4023-4023
4023 Background: Biliary tract cancers (BTC) are increasingly subtyped by molecular alterations, but little is known about the relationship between gain-of-function mutations and the RNA transcript expression of immune-related pathways. Methods: A sa
Autor:
Walid L. Shaib, Gregory B. Lesinski, Olatunji B. Alese, Maria Diab, Manali Rupji, Mehmet Akce, Jeffrey M. Switchenko, Bassel F. El-Rayes, Christina Wu
Publikováno v:
Journal of Clinical Oncology. 39:95-95
95 Background: Preclinical data suggests metformin can improve immune exhaustion of tumor infiltrating lymphocytes and potentiate the effects of PD-1 blockade. By normalizing the hypoxic TME, metformin was shown to improve cytotoxic T cell function a
Autor:
Gregory B. Lesinski, Anthony P. Martinez, Terrence L. Fisher, Elizabeth E. Evans, Michael C. Lowe, Melanie Allor, Brian Olson, Melinda L. Yushak, Crystal Mallow, Christine Reilly, Keith A. Delman, Ragini R. Kudchadkar, Jacklyn Hammons
Publikováno v:
Journal of Clinical Oncology. 38:10061-10061
10061 Background: SEMA4D has broad immunomodulatory effects in the tumor microenvironment (TME); blocking SEMA4D in combination with checkpoint inhibitors (CI) promotes immune infiltration, reduces recruitment of myeloid cells, enhances T cell activi
Autor:
Walid L. Shaib, Gregory B. Lesinski, Christina Wu, Mehmet Akce, Olatunji B. Alese, Bassel F. El-Rayes
Publikováno v:
Journal of Clinical Oncology. 38:TPS269-TPS269
TPS269 Background: Panitumumab (Pmab) is a recombinant monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR), and is indicated for metastatic colorectal carcinoma (mCRC). EGFR inhibition induces synthetic le
Autor:
Gregory B. Lesinski, Olatunji B. Alese, Christina Wu, Walid L. Shaib, Mehmet Akce, Bassel F. El-Rayes
Publikováno v:
Journal of Clinical Oncology. 38:830-830
830 Background: XL888 is a selective inhibitor of heat shock protein 90 (HSP90). It modulates several oncogenic signaling pathways, and the tumor microenvironment. In preclinical models, XL888 potentiates efficacy of PD-1 inhibition. We report the re
Autor:
Edmund K. Waller, Lily Yang, Gregory B. Lesinski, Ramireddy Bommireddy, Brianna Flynn, Alexandra Waller, Christopher T. Petersen, Bassel F. El-Rayes, Mohammad Raheel Jajja, Sruthi Ravindranathan, Periasamy Selvaraj
Publikováno v:
Journal of Clinical Oncology. 37:e15183-e15183
e15183 Background: Current immunotherapies fail to benefit patients with colon cancer, largely due to high molecular heterogeneity and low frequencies of tumor infiltrating lymphocytes. In this study, we are addressing this limitation via a novel tec
Autor:
Michael C. Lowe, Gregory B. Lesinski, Ragini R. Kudchadkar, Keith A. Delman, Terrence L. Fisher, Melinda L. Yushak, Elizabeth E. Evans
Publikováno v:
Journal of Clinical Oncology. 37:TPS9603-TPS9603
TPS9603 Background: Interrogation of the tumor microenvironment (TME) is crucial to provide insight into biological activity, resistance mechanisms and implementation of rational combination immunotherapies. Semaphorin 4D (SEMA4D, CD100) has broad im
Autor:
Mehmet Akce, Bassel F. El-Rayes, Gregory B. Lesinski, Olatunji B. Alese, Christina Wu, Walid L. Shaib
Publikováno v:
Journal of Clinical Oncology. 36:TPS526-TPS526
TPS526 Background: Heat shock protein 90 (HSP90) has a central role in modulating tumor microenvironment, inflammatory signaling pathways (NF-κB, HIF-1α and Jak-STAT), tumor antigen presentation and expression, PD-L1 expression and macrophage migra
Publikováno v:
Journal of Clinical Oncology. 35:e21014-e21014
e21014 Background: Limited effective therapies exist for patients with melanoma after progression on immune- and targeted-therapies. Treatment with selinexor, a potent small molecule inhibitor of exportin-1 (CRM/XPO1), results in nuclear retention of